Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
Polymorphisms and interspecies differences of the activating and inhibitory FcγRII of Macaca nemestrina influence the binding of human IgG subclasses

Trist HM, Tan PS, Wines BD, Ramsland PA, Orlowski E, Stubbs J, Gardiner EE, Pietersz GA, Kent SJ, Stratov I, Burton DR, Hogarth PM

(2014), J Immunol, 192(2), 792-803

Optimal approach for high-risk acute promyelocytic leukemia

Iland HJ, Seymour JF, Wei A

(2014), Curr Opin Hematol, 21(2), 102-13

Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients

Govindaraj C, Tan P, Walker P, Wei A, Spencer A, Plebanski M

(2014), Clin Cancer Res, 20(3), 724-35

Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients

Govindaraj C, Madondo M, Kong YY, Tan P, Wei A, Plebanski M

(2014), Am J Hematol, 89(8), 795-802

Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care

Iland HJ, Wei A, Seymour JF

(2014), Best Pract Res Clin Haematol, 27(1), 39-52

Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome

Tan P, Wei A, Mithraprabhu S, Cummings N, Liu HB, Perugini M, Reed K, Avery S, Patil S, Walker P, Mollee P, Grigg A, D'Andrea R, Dear A, Spencer A

(2014), Blood Cancer J, 4, e170

Causes and clinical significance of prolonged activated partial thromboplastin times in thalassaemia major

McFadyen J, Butler J, Malan E, Tran H

(2014), Ann Hematol, 93(5), 867-8

Prothrombin complex concentrate safely reverses warfarin-related bleeding

Tran H, Chunilal S

(2014), Evid Based Med, 19(2), 75

A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study)

Tran H, Brighton T, Grigg A, McRae S, Dixon J, Thurley D, Gandhi MK, Truman M, Marlton P, Catalano J

(2014), Br J Haematol, 167(2), 243-51

An update of consensus guidelines for warfarin reversal

Tran HA, Chunilal SD, Tran H

(2014), Med J Aust, 200(2), 82

The successful management of dabigatran-associated critical end-organ bleeding with recombinant factor VIIa

Htun KT, McFadyen J, Tran HA

(2014), Ann Hematol, 93(10), 1785-6

Angiotensin-converting enzyme 2 mediates hyperfiltration associated with diabetes

Tikellis C, Brown R, Head GA, Cooper ME, Thomas MC

(2014), Am J Physiol Renal Physiol, 306(7), F773-80

Underestimation of myelodysplastic syndrome incidence by cancer registries: results from a population-based data linkage study

McQuilten ZK, Wood EM, Polizzotto MN, Campbell LJ, Wall M, Curtis DJ, Farrugia H, McNeil JJ, Sundararajan V

(2014), Cancer, 120(11), 1686-94

Anti-lysophosphatidic acid antibodies improve traumatic brain injury outcomes

Crack PJ, Zhang M, Morganti-Kossmann MC, Morris AJ, Wojciak JM, Fleming JK, Karve I, Wright D, Sashindranath M, Goldshmit Y, Conquest A, Daglas M, Johnston LA, Medcalf RL, Sabbadini RA, Pébay A

(2014), J Neuroinflammation, 11, 37

Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL

McCormack MP, Shields BJ, Jackson JT, Nasa C, Shi W, Slater NJ, Tremblay CS, Rabbitts TH, Curtis DJ

(2013), Blood, 122(12), 2093-103

Cardiac imaging in FIP1L1-PDGFRA

Jaworski C, Looi JL, Martin J, Bergin P, Hare J, Kaye D, Wei A, Taylor AJ

(2013), J Am Coll Cardiol, 62(14), 1304

Stem cells behind the barrier

Cangkrama M, Ting SB, Darido C

(2013), Int J Mol Sci, 14(7), 13670-86

The regulation of mitochondrial metabolism by the Bcl-2fFamily of pro-survival proteins: new therapeutic opportunities for targeting cancer cells

Wei A, Brown M, Guthridge MA

(2013), J Hematol Thromb Dis, 1(4), 121

Efficacy, safety and survival with ruxolitinib in patients with smyelofibrosis: results of a median 2-year follow-up of COMFORT-I

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarj

(2013), Haematologica, 98(12), 1865-71

An investigation on platelet transport during thrombus formation at micro-scale stenosis

Tovar-Lopez FJ, Rosengarten G, Nasabi M, Sivan V, Khoshmanesh K, Jackson SP, Mitchell A, Nesbitt WS

(2013), PLoS One, 8(10), e74123

23 24 25 26 27